Clarisse Audigier-Valette - JoVE Visualize

Showing results (71-80 of 82) with videos related to

Pageof 9

Sort By:

Journal for Immunotherapy of Cancer|February 1, 2023

First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817Neal E Ready, Clarisse Audigier-Valette, Jonathan W Goldman, et al.

Lancet (London, England)|January 19, 2016

Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)Fabrice Barlesi, Julien Mazieres, Jean-Philippe Merlio, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2022

Comprehensive Genome Profiling in Patients With Metastatic Non-Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 TrialFabrice Barlesi, Pascale Tomasini, Maryam Karimi, et al.

The Lancet. Oncology|August 12, 2024

Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7-IFCT-1402): a multicentre, randomised, controlled phase 2 trialPierre Vera, Sébastien Thureau, Florence Le Tinier, et al.

European Journal of Cancer (Oxford, England : 1990)|May 22, 2021

Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamicsLaura Mezquita, Isabel Preeshagul, Edouard Auclin, et al.

European Journal of Cancer (Oxford, England : 1990)|March 21, 2022

Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterationsMariona Riudavets, Edouard Auclin, Miguel Mosteiro, et al.

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 27, 2025

Prognostic Value of FDG PET Metabolic Parameters Before and After 42 Gy of Radiochemotherapy in Patients with Inoperable Stage III Nonsmall Cell Lung CancerPierre Vera, Philippe Giraud, Sébastien Hapdey, et al.

Nature Medicine|February 4, 2022

Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancerLisa Derosa, Bertrand Routy, Andrew Maltez Thomas, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 14, 2021

First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 TrialLuis G Paz-Ares, Suresh S Ramalingam, Tudor-Eliade Ciuleanu, et al.

Clinical Lung Cancer|December 17, 2023

Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung CancerMariona Riudavets, Edouard Auclin, Miguel Mosteiro, et al.

Pageof 9

Showing results (71-80 of 82) with videos related to

Sort By:

Pageof 9

Journal for Immunotherapy of Cancer|February 1, 2023

First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817Neal E Ready, Clarisse Audigier-Valette, Jonathan W Goldman, et al.

Lancet (London, England)|January 19, 2016

Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)Fabrice Barlesi, Julien Mazieres, Jean-Philippe Merlio, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2022

Comprehensive Genome Profiling in Patients With Metastatic Non-Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 TrialFabrice Barlesi, Pascale Tomasini, Maryam Karimi, et al.

The Lancet. Oncology|August 12, 2024

Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7-IFCT-1402): a multicentre, randomised, controlled phase 2 trialPierre Vera, Sébastien Thureau, Florence Le Tinier, et al.

European Journal of Cancer (Oxford, England : 1990)|May 22, 2021

Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamicsLaura Mezquita, Isabel Preeshagul, Edouard Auclin, et al.

European Journal of Cancer (Oxford, England : 1990)|March 21, 2022

Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterationsMariona Riudavets, Edouard Auclin, Miguel Mosteiro, et al.

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 27, 2025

Prognostic Value of FDG PET Metabolic Parameters Before and After 42 Gy of Radiochemotherapy in Patients with Inoperable Stage III Nonsmall Cell Lung CancerPierre Vera, Philippe Giraud, Sébastien Hapdey, et al.

Nature Medicine|February 4, 2022

Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancerLisa Derosa, Bertrand Routy, Andrew Maltez Thomas, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 14, 2021

First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 TrialLuis G Paz-Ares, Suresh S Ramalingam, Tudor-Eliade Ciuleanu, et al.

Clinical Lung Cancer|December 17, 2023

Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung CancerMariona Riudavets, Edouard Auclin, Miguel Mosteiro, et al.

Pageof 9